Figure 1.

Effect of combined P2Y₁₂ and GPIIb‐IIIa inhibition on ADP‐ or collagen‐induced platelet aggregation. Platelet‐rich plasma (PRP) was prepared from PPACK‐anticoagulated blood treated with vehicle or R‐138727 5 μmol/L in the absence or presence of abciximab 3 μg/mL or eptifibatide 0.9 μg/mL. PRP was stimulated with ADP 20 μmol/L or collagen 20 μg/mL and the extent of platelet aggregation was determined. Data are reported as mean± SEM from 6 experiments. *P<0.0071 vs no R‐138727, vehicle treatment; ⁺P<0.0071 vs corresponding treatment in the absence of R‐138727; ^#P<0.0071 vs R‐138727, vehicle treatment. GP indicates glycoprotein; PPACK, d‐Phe‐Pro‐Arg‐chloromethylketone.